CAHHealthcare · Medical DistributionThe 17 Wall Street analysts covering Cardinal Health, Inc. hold a median 12-month price target of $258 — +9.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Cardinal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Accruals (61): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Cardinal Health, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CAH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.5% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 July 2026 | Citigroup | Maintains | Buy | $245 → $265 |
| 23 July 2026 | Mizuho | Maintains | Outperform | $235 → $240 |
| 20 July 2026 | UBS | Maintains | Buy | $260 → $274 |
| 9 July 2026 | TD Cowen | Maintains | Buy | $255 → $275 |
| 9 July 2026 | TD Cowen | Maintains | Buy | — |
| 2 July 2026 | B of A Securities | Maintains | Buy | $240 → $260 |
| 2 July 2026 | B of A Securities | Maintains | Buy | — |
| 4 May 2026 | JP Morgan | Maintains | Neutral | — |
| 1 May 2026 | Citigroup | Maintains | Buy | — |
| 1 May 2026 | TD Cowen | Maintains | Buy | — |
| 1 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 Apr 2026 | William Blair | Initiates | Outperform | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 24 Feb 2026 | Barclays | Maintains | Overweight | — |
| 10 Feb 2026 | JP Morgan | Maintains | Neutral | — |
| 10 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 Feb 2026 | Mizuho | Maintains | Outperform | — |
| 29 Jan 2026 | Morgan Stanley | Maintains | Overweight | — |
| 15 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Jan 2026 | Citigroup | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 92% of US stocks
Cheaper than 98% of US stocks
Cheaper than 24% of US stocks
Higher than 57% of US stocks
Higher than 19% of US stocks
Higher than 7% of US stocks
Higher than 50% of US stocks
Higher than 48% of US stocks
Higher than 19% of US stocks
Higher than 69% of US stocks
Higher than 20% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| CAHCardinal Health, Inc. | $55.2B | 94 |
| CORCencora, Inc. | $60.4B | 48 |
| MCKMcKesson Corp. | $100.2B | 73 |
| HSICHenry Schein, Inc. | $9.8B | 78 |
| MDLNMedline, Inc.* | $51.6B | 9 |
| EWEdwards Lifesciences Corp.* | $49.6B | 86 |
| BDXBecton, Dickinson & Co.* | $45.6B | 95 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAH appears on the weeks it earns a place.
Cardinal Health (CAH) closed its most recent trading day at $235.6, up 2.42% from the previous session, outperforming the broader market. The Zacks article highlights this share-price move for investors to note.
Why it matters — A CAH watcher would care because the stock's advance against the broader market reflects a notable shift in its recent trading performance.
Zacks Investment Research published an article stating that Cardinal Health is well positioned to outperform the market due to its above-average growth in financials.
Why it matters — The article suggests Cardinal Health's financial growth profile could make it attractive to growth-focused investors reviewing the stock.
Zacks Investment Research highlighted Cardinal Health (CAH) as a top growth stock for the long-term, referencing the Zacks Style Scores system for identifying top-rated stocks.
Why it matters — A positive assessment from Zacks Research may influence investor perception of CAH's long-term growth prospects.
Zacks Investment Research published an article suggesting that investors should take advantage of medical stocks now, using the Zacks Earnings ESP method to identify potential earnings surprises.
Why it matters — As a medical sector stock, Cardinal Health could be among the stocks that investors target using this earnings-surprise strategy.
Cardinal Health (CAH) closed at $232.51, up 1.38% from the prior trading day, outperforming the broader stock market.
Why it matters — A share-price increase that outpaces the market suggests positive investor sentiment around Cardinal Health on that trading day.
The 17 Wall Street analysts covering Cardinal Health, Inc. have a median 12-month price target of $258, with estimates ranging from $215 to $275. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Cardinal Health, Inc., 14 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardinal Health, Inc. 94 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Cardinal Health, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +9.5% from the last close, and Ticker Nerd's factor model ranks Cardinal Health, Inc. 94 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cardinal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $215 to $275 over the next 12 months.
Cardinal Health, Inc. returned +52.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Cardinal Health Inc. is a healthcare services and products company that supports the movement of medicines, medical supplies, and clinical products across the healthcare system.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know". Cardinal Health (CAH) closed its most recent trading day at $235.6, up 2.42% from the previous session, outperforming the broader market. The Zacks article highlights this share-price move for investors to note.
Cardinal Health Inc. is a healthcare services and products company that supports the movement of medicines, medical supplies, and clinical products across the healthcare system. The company distributes branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and other healthcare providers, while also supplying medical-surgical products and equipment to facilities in North America, Europe, and Asia. Its offerings include customized solutions for hospitals, health systems, ambulatory surgery centers, clinical laboratories, and physician offices, along with performance and data solutions designed to improve supply chain efficiency. Cardinal Health plays a central role in medical distribution, helping connect manufacturers, providers, and care settings through large-scale logistics and product support. Headquartered in Dublin, Ohio, Cardinal Health is a major participant in the healthcare supply chain and serves a broad range of customers across the industry.
CEO Mr. Jason M. Hollar · 53,084 employees · United States · https://www.cardinalhealth.com